Press Releases

Celleron Therapeutics publishes new findings showing immune modulation underpins the anti-cancer effects of zabinostat

Apr 2, 2021

Oxford, April 2nd, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, has worked closely with

Celleron’s Chief Medical Officer David Kerr to Deliver Guest Presentation at WuXi Healthcare Forum 2021

Mar 1, 2021

Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by

Celleron Therapeutics announces approval of China IND Registration Clinical Trial with partner Nuance Biotech

Jan 20, 2021

Oxford, UK, 20 January 2021 – Celleron Therapeutics, the Oxford-based UK company developing novel medicines to treat cancer, today announced that

Celleron Therapeutics Spins Out SynOx Therapeutics which Secures EUR 37M to Develop Emactuzumab

Nov 30, 2020

Oxford, November 30, 2020 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announces the formation of

Celleron Therapeutics presents at the opening ceremony of BIO-FORUM 2020 held in China

Sep 24, 2020

Oxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage

Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour

Aug 12, 2020

Oxford, 12th August 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing

Celleron Therapeutics Chief Medical Officer Prof David Kerr Leads Opening of University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer

May 18, 2020

Oxford, UK / Sichuan, China, 15 May 2020 Today marks the launch of the University of Oxford-Sichuan University Huaxi Joint